Literature DB >> 26284971

Effect of IL28B genotype on hepatitis B and C virus infection.

Albert Friedrich Stättermayer1, Peter Ferenci2.   

Abstract

Genetic factors play a major role for treatment response and disease progression of chronic hepatitis B (HBV) and C virus (HCV) infection. In 2009 a genome-wide association study (GWAS) identified a single nucleotide polymorphism near the IL28B gene that was associated with treatment-induced viral clearance in chronic HCV infection treated with pegylated interferon-α (PEG-IFN) and ribavirin (RBV). Further, another GWAS found an association between IL28B genotype and spontaneous viral clearance in acute HCV infection. The effect on sustained viral response (SVR) could also be observed in patients receiving a triple-therapy with a direct antiviral agent (DAA) combined with PEG-IFN/RBV. In the era of all-oral interferon-free treatment regimens with the combination of different DAAs-with SVR rates exceeding 90%-the effect of IL28B was blunt. In contrast, in HBV several retrospective studies yielded conflicting results of the association of IL28B with PEG-IFN-induced treatment response.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26284971     DOI: 10.1016/j.coviro.2015.07.011

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  11 in total

1.  HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Authors:  Harel Dahari; Laetitia Canini; Frederik Graw; Susan L Uprichard; Evaldo S A Araújo; Guillaume Penaranda; Emilie Coquet; Laurent Chiche; Aurelie Riso; Christophe Renou; Marc Bourliere; Scott J Cotler; Philippe Halfon
Journal:  J Hepatol       Date:  2016-02-22       Impact factor: 25.083

Review 2.  Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.

Authors:  Qiu-Feng He; Qiong-Fang Zhang; Da-Zhi Zhang
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

3.  An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms.

Authors:  Darragh Duffy; Estelle Mottez; Shaun Ainsworth; Tan-Phuc Buivan; Aurelie Baudin; Muriel Vray; Ben Reed; Arnaud Fontanet; Alexandra Rohel; Ventzislava Petrov-Sanchez; Laurent Abel; Ioannis Theodorou; Gino Miele; Stanislas Pol; Matthew L Albert
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

4.  Association between genetic polymorphisms of the IL28B gene and leukomonocyte in Chinese hepatitis B virus-infected individuals.

Authors:  Yuzhu Song; Yunsong Shen; Xueshan Xia; A-Mei Zhang
Journal:  PeerJ       Date:  2017-12-19       Impact factor: 2.984

Review 5.  Hepatitis B virus infection and alcohol consumption.

Authors:  Ayako Iida-Ueno; Masaru Enomoto; Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

6.  An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.

Authors:  Yutaka Furutani; Mariko Toguchi; Yumi Shiozaki-Sato; Xian-Yang Qin; Etsuko Ebisui; Shoko Higuchi; Masayuki Sudoh; Harukazu Suzuki; Nobuaki Takahashi; Koichi Watashi; Takaji Wakita; Hideaki Kakeya; Soichi Kojima
Journal:  PLoS One       Date:  2019-06-12       Impact factor: 3.240

7.  Relationship of genetic polymorphisms in CTLA-4 and IL-18 with viral hepatitis: evidence from a meta-analysis.

Authors:  Yang Yu; Jie Qu; Chen Zhou; Guangqiang You
Journal:  Epidemiol Infect       Date:  2019-12-05       Impact factor: 2.451

Review 8.  Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies.

Authors:  Laura A Novotny; John Grayson Evans; Lishan Su; Haitao Guo; Eric G Meissner
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.048

9.  HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.

Authors:  Valli De Re; Mariangela De Zorzi; Laura Caggiari; Gianfranco Lauletta; Maria Lina Tornesello; Elisa Fognani; Marta Miorin; Vito Racanelli; Luca Quartuccio; Laura Gragnani; Sabino Russi; Fabio Pavone; Michela Ghersetti; Elena Garlatti Costa; Pietro Casarin; Riccardo Bomben; Cesare Mazzaro; Giancarlo Basaglia; Massimiliano Berretta; Emanuela Vaccher; Francesco Izzo; Franco Maria Buonaguro; Salvatore De Vita; Anna Linda Zignego; Paolo De Paoli; Riccardo Dolcetti
Journal:  Oncotarget       Date:  2016-06-21

10.  Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy.

Authors:  Jessica Cusato; Lucio Boglione; Amedeo De Nicolò; Gian Paolo Caviglia; Simone Mornese Pinna; Alessia Ciancio; Giulia Troshina; Antonina Smedile; Miriam Antonucci; Valeria Avataneo; Alice Palermiti; Jacopo Mula; Alessandra Manca; Giuseppe Cariti; Marco Cantù; Giorgio Maria Saracco; Giovanni Di Perri; Antonio D'Avolio
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.